| Literature DB >> 24561744 |
Bing-Ching Ho1, I-Shing Yu2, Li-Fan Lu3, Alexander Rudensky4, Hsuan-Yu Chen5, Chang-Wu Tsai2, Yih-Leong Chang6, Chen-Tu Wu6, Luan-Yin Chang7, Shin-Ru Shih8, Shu-Wha Lin9, Chun-Nan Lee9, Pan-Chyr Yang10, Sung-Liang Yu11.
Abstract
There are no antivirals or vaccines available to treat Enterovirus 71 (EV71) infections. Although the type I interferon response, elicited upon virus infection, is critical to establishing host antiviral innate immunity, EV71 fails to induce this response efficiently. Here we provide new insights into potential anti-EV71 therapy by showing that neutralization of EV71-induced miR-146a prevents death in mice by restarting the production of type I interferon. EV71 infection upregulates miR-146a, which targets IRAK1 and TRAF6 involved in TLR signalling and type I interferon production. We further identify AP1 as being responsible for the EV71-induced expression of miR-146a. Surprisingly, knocking out miR-146a or neutralizing virus-induced miR-146a by specific antagomiR restores expressions of IRAK1 and TRAF6, augments IFNβ production, inhibits viral propagation and improves survival in the mouse model. Our results suggest that enterovirus-induced miR-146a facilitates viral pathogenesis by suppressing IFN production and provide a clue to developing preventive and therapeutic strategies for enterovirus infections.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24561744 DOI: 10.1038/ncomms4344
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919